The global injectable drug delivery market is expected to reach a value of $29,981 million in 2015 up from $14,994 million in 2009 according to a recent report by Markets and Markets. This surge is being driven by growing areas of development such as the launch of biologic drugs, which are patient self-injected, usability and patient compliant devices. Currently, half of the top ten selling drugs are delivered parentally and one is delivered by inhaler. Touching on these trends and others; parenteral delivery, injection mechanics and novel auto syringe platforms, the event will look at the current and future opportunities in the injectable drug market.
Despite the market growth, industry is still facing a number of challenges and these too will be addressed by Sagentia and experts in the field at the event. For example, the industry must still tackle how to; secure funding for new technologies, deal with an increase in comorbidities associated with chronic diseases and human factors such as the administration of drug delivery in the home.
Dr Berman comments: “Drug delivery forms the linkage between the pharmaceutical product and advanced devices, which can provide benefits to the patient, the healthcare professional and the industry. We have worked with the organising committee to ensure that pressing industry issues are discussed such as the market opportunity, growth and innovation and how drug delivery devices can deliver an improved patient experience.”
The drug delivery market is an active and growing area for Sagentia. The company is experiencing increased interest from customers across the drug delivery landscape, particularly around market analysis, new concept generation, product development, design reviewing and problem solving. Sagentia’s work in this area covers a broad range of delivery modalities, such as inhalers, injectors, sprays, photodynamic therapy, pumps and patches.
Dr Andrew Jackson, Head of Patient Care at Sagentia, comments: “Injectable drug delivery is advancing. Earlier this year we saw the launch of the first talking drug delivery device, the Sanofi Auvi-Q, and pharma companies are increasingly trying to deliver more viscous formulations and larger volumes subcutaneously. With regulators now wanting to see hard evidence of effective delivery device use by patients, devices are becoming an increasingly important component of drug delivery. Sagentia’s track record in usability and medical device design, as well as our ISO 13485 accreditation, makes us well placed to help companies with their device development programmes.”
The full event agenda can be found here.
_________________________________________